Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rovafovir etalafenamide - Gilead Sciences

Drug Profile

Rovafovir etalafenamide - Gilead Sciences

Alternative Names: GS 9148 phosphonoamidate prodrug; GS-9131

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antiretrovirals; Furans; Phosphoric Acids; Propionates; Purine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended HIV-1 infections

Most Recent Events

  • 26 Apr 2022 No development reported - Phase-II for HIV-1 infections (Treatment-experienced) in Zimbabwe, Uganda (PO)
  • 28 Apr 2020 Gilead Sciences terminates a phase II trial in HIV-1 infections (Treatment-experienced) in Zimbabwe and Uganda and Zimbabwe due to failure of meeting targeted antiviral response (PO, Tablet) (NCT03472326)
  • 03 Apr 2018 Phase-II clinical trials in HIV-1 infections (Treatment-experienced) in Uganda (PO, Tablet) (NCT03472326)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top